StreetInsider.com News Articles

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Wed, 22 Jul 2026 14:45:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.

This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.

Figures –

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Wed, 22 Jul 2026 14:45:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures –

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Wed, 22 Jul 2026 14:45:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures –

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Wed, 22 Jul 2026 14:45:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures –

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Wed, 22 Jul 2026 14:45:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures –

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Wed, 22 Jul 2026 14:45:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures –

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Wed, 22 Jul 2026 14:45:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures –

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Wed, 22 Jul 2026 14:45:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures –

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Wed, 22 Jul 2026 14:45:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures –

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Wed, 22 Jul 2026 14:45:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures –

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Wed, 22 Jul 2026 14:45:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures –

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Wed, 22 Jul 2026 14:45:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures –

Celyad Oncology raises €500,000 via Fortress private placement

Tue, 14 Jul 2026 03:32:18 -0400

Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.

Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.

Following the share issuance, Fortress is expected to hold approximately 60.52% of

Celyad Oncology raises €500,000 via Fortress private placement

Tue, 14 Jul 2026 03:32:18 -0400

Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.

Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.

Following the share issuance, Fortress is expected to hold approximately 60.52% of

Celyad Oncology raises €500,000 via Fortress private placement

Tue, 14 Jul 2026 03:32:18 -0400

Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.

Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.

Following the share issuance, Fortress is expected to hold approximately 60.52% of

Celyad Oncology raises €500,000 via Fortress private placement

Tue, 14 Jul 2026 03:32:18 -0400

Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.

Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.

Following the share issuance, Fortress is expected to hold approximately 60.52% of

Celyad Oncology raises €500,000 via Fortress private placement

Tue, 14 Jul 2026 03:32:18 -0400

Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.

Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.

Following the share issuance, Fortress is expected to hold approximately 60.52% of

Celyad Oncology raises €500,000 via Fortress private placement

Tue, 14 Jul 2026 03:32:18 -0400

Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.

Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.

Following the share issuance, Fortress is expected to hold approximately 60.52% of

Celyad Oncology Announces €500,000 Private Placement

Tue, 14 Jul 2026 03:32:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology SA (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”).
Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted

Celyad Oncology Announces €500,000 Private Placement

Tue, 14 Jul 2026 03:32:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology SA (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”).
Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted

Celyad Oncology Announces €500,000 Private Placement

Tue, 14 Jul 2026 03:32:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology SA (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”).
Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted

Celyad Oncology Announces €500,000 Private Placement

Tue, 14 Jul 2026 03:32:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology SA (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”).
Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted

Celyad Oncology Announces €500,000 Private Placement

Tue, 14 Jul 2026 03:32:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology SA (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”).
Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted

Celyad Oncology Announces €500,000 Private Placement

Tue, 14 Jul 2026 03:32:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology SA (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”).
Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted

Celyad Oncology Announces €500,000 Private Placement

Tue, 14 Jul 2026 03:32:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology SA (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”).
Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted